Strengthening Infection Prevention and Responsible Antibiotic Use through Communication and Teamwork

Published on
November 15, 2026

Medical Services, BMH Group of Hospitals, Kozhikode, Kerala

Areas of Expertise
Infectious diseases, Infection prevention, Control, Antimicrobial stewardship, clinical governance

Consider a patient recovering after abdominal surgery. On the second postoperative day, a nurse notes that the urinary catheter no longer has a clear indication. A pharmacist asks why empirical intravenous antibiotics are continuing without a documented review. The laboratory reports a culture result that would allow a narrower-spectrum drug. Each observation is clinically actionable, but its value depends on whether it reaches someone with the authority to act, and whether that person acts. Each additional catheter-day adds to the risk of catheter-associated urinary tract infection; each unnecessary antibiotic-day adds to the risk of adverse drug effects, Clostridioides difficile infection and selection for resistant bacteria.

Infection prevention and control (IPC) and antimicrobial stewardship (AMS) are delivered through thousands of such exchanges every day. They depend not only on what individual clinicians know, but on how reliably a team moves information to the point of decision. My view is that health systems should treat these exchanges as a component of clinical care that can be designed, resourced and measured: protected time, defined responders and verification that decisions are carried out. A guideline describes what should happen; team processes determine whether it does.

The two disciplines act on the same causal chain. Every infection prevented removes a reason to prescribe antibiotics. Every unnecessary antibiotic exposure avoided reduces adverse drug effects and the selection pressure under which resistant bacteria outcompete susceptible ones. Resistance is a property of microorganisms, not of patients: it arises through genetic mutation and the acquisition of resistance genes, and it spreads in hospitals both through antibiotic selection and through transmission between patients via hands, equipment and the environment. Stewardship addresses the first route and infection prevention the second, which is why the two work best as partners rather than as separate programmes.

The strongest quantitative support comes from a meta-analysis of 32 hospital studies covering more than 9 million patient-days.[1] Stewardship programmes were associated with a 51% reduction in the incidence of infection or colonisation (carriage without disease) with multidrug-resistant Gram-negative bacteria, a 37% reduction for meticillin-resistant Staphylococcus aureus (MRSA) and a 32% reduction for C. difficile infection. Effects were larger when stewardship was combined with infection-control measures (pooled incidence ratio 0.69) and largest when those measures included hand hygiene (0.34, roughly a two-thirds reduction). No effect was detected for vancomycin-resistant enterococci.[1] These findings support coordinating the two programmes while preserving the distinct expertise each requires.

These estimates need careful interpretation. The included studies were largely observational, comparing incidence before and after implementation, and so cannot fully separate a programme’s effect from background trends or concurrent changes; heterogeneity between studies was also substantial. The programmes were multicomponent, combining education, prescription audit with feedback, restriction and changes in working practice, so their results cannot isolate the contribution of communication itself. A scoping review of 53 studies of hospital team communication found that structuring the content or process of team discussion was the most common intervention, yet only four studies linked better communication with IPC or AMS outcomes, and the evidence did not allow effectiveness to be estimated. All 53 studies came from high-income countries.[2] Communication is therefore a plausible and important mechanism whose effect size, and transferability to resource-limited settings, remain to be established. We should invest in it while studying it.

A brief, structured daily review can link the two disciplines at the bedside. Four questions cover most of the ground. Does each invasive device, such as a urinary catheter or central venous line, still have a valid indication? What working diagnosis justifies the antibiotic? Have microbiology or other results changed the picture? What must happen today, and who will do it? Assigning each decision to a named person turns discussion into accountable action, and the same structure makes the process auditable.

A formal antibiotic review 48–72 hours after treatment begins, sometimes called an antibiotic time-out, is a sensible default because culture results and the clinical trajectory are usually available by then. Review should happen earlier if new information arrives or the patient deteriorates. The team decides whether to continue, narrow (de-escalate), broaden or stop treatment; whether intravenous therapy can be switched to oral, which also shortens exposure to vascular lines; and what total duration the evidence supports for that infection. Prescribing authority remains with the treating clinician, while nurses, pharmacists and laboratory staff contribute observations that improve the decision.

Stewardship is not the same as restriction. In sepsis and other serious bacterial infections, delay in effective treatment is associated with worse outcomes, so review processes must never obstruct urgent therapy. The counterpart is that empirical treatment, started before the cause is known, should carry a documented plan to reassess both the diagnosis and the prescription.

Laboratory communication needs the same closed-loop discipline used in medication safety. A critical result, such as a positive blood culture, becomes useful only when someone receives it, interprets it in the patient’s clinical context and confirms the action taken. If that person is unavailable, a predefined escalation route is needed. Uploading a report to the electronic record is one step in this loop, not its completion.

Diagnostic technology should therefore be judged against the whole pathway, not laboratory speed alone. The FAST randomised trial included 850 patients with Gram-negative bloodstream infection at seven centres in Greece, India, Israel and Spain, all settings with high antimicrobial resistance.[3] Rapid susceptibility testing performed directly from positive blood cultures delivered results in about 7.5 hours, compared with about 44 hours for standard methods, and led to earlier escalation or de-escalation of antibiotics. It was not, however, superior on the primary endpoint, a desirability-of-outcome ranking at 30 days that combined survival, clinical response, discharge status and harms such as kidney injury or acquisition of resistant organisms. Both groups received stewardship review.[3] Faster information is necessary but not sufficient: patient benefit depends on what the clinical system does with it, and has to be measured rather than assumed.

Professional hierarchy is a well-described barrier to safety communication. A junior doctor may hesitate to question a senior colleague’s prescription. A nurse may recognise a concern but regard prescribing as outside the nursing role. A pharmacist’s recommendation may arrive after the ward round, once decisions have been made. Teams whose members can raise concerns without fear of embarrassment, a condition organisational researchers call psychological safety, are more likely to surface this kind of information. Leaders build it by inviting questions, clarifying roles and responding constructively when concerns are raised.

Shared responsibility needs defined authority. Nurses can prompt review and report changes in the patient’s condition; pharmacists can assess dose, drug interactions, adjustment for kidney function and treatment duration; laboratory professionals can explain what a result does and does not establish, for example whether an organism is more likely a contaminant or colonising organism than a cause of infection. The treating clinician integrates these inputs and documents the plan. An unresolved disagreement should have an agreed route to a senior decision-maker, so that concerns are resolved rather than dropped.

Teamwork must also include staff whose work interrupts transmission directly. Environmental cleaning staff need clear protocols for shared equipment and isolation rooms, and a way to report missing supplies, because contaminated surfaces and equipment are recognised reservoirs for C. difficile spores and multidrug-resistant Gram-negative bacteria. Laboratory staff need relevant clinical information to process and interpret specimens appropriately. At transfer and discharge, receiving teams need the indication for treatment, pending results and the next review or planned stop date; these transitions are points at which information is commonly lost.

Patients and families also need explanations they can use. When antibiotics are not indicated, clinicians should explain the likely cause of the illness (often a viral infection, against which antibiotics have no effect), what will help and which warning signs should prompt a return. When antibiotics are prescribed, the plan and its review point should be explained. Questions should be welcomed without shifting to patients the responsibility for policing their own safety.

Students should practise these conversations across professional boundaries. Interprofessional case discussions can teach future doctors, nurses and pharmacists to disagree constructively, acknowledge diagnostic uncertainty and escalate appropriately. These competencies deserve formal assessment alongside scientific knowledge.

Communication operates within structural constraints. Overcrowding, inadequate nurse staffing, unreliable water supply, shortages of alcohol-based hand rub and poor access to diagnostics cannot be corrected by training alone; they are upstream drivers of both transmission and empirical prescribing. Hospital leaders and policymakers should fund these essentials alongside protected time for joint review. In smaller facilities, trained local teams supported remotely by regional specialists may be a workable model, but its effectiveness and cost-effectiveness need formal evaluation.

I would begin with a small, balanced set of indicators. Process measures could include the proportion of device-days with a documented indication, the proportion of antibiotic courses reviewed within 72 hours and the time from a critical result to a documented clinical decision. Outcome measures could include healthcare-associated infection rates per 1,000 device-days or patient-days, C. difficile incidence and, where feasible, resistance trends. Balancing measures guard against unintended harm: time to effective treatment in sepsis, mortality, readmission and staff workload. Comparing units or hospitals requires standardised surveillance definitions and adjustment for case mix, because sicker patient populations have higher infection rates irrespective of care quality.

Teams should review these data regularly, using methods such as statistical process control charts that help distinguish genuine change from random variation. A rise in reported infections may reflect better case detection rather than poorer care, and should be investigated before conclusions are drawn. Reviews should focus on system failures rather than individual blame, and staff should hear what changed as a result of their reports.

For regulators and funders, the relevant question is whether a programme changes care, not merely whether it exists. A committee roster or annual training attendance cannot answer that question. Assessment standards should instead sample individual cases, examine whether recommendations were acted on and test whether staff can raise concerns. Funding should support these functions in community care as well as in hospitals.

Digital systems and artificial intelligence may help flag overdue reviews, identify devices without a documented indication or route urgent results to the right clinician. Their value will depend on data quality, alert burden (too many alerts lead to alert fatigue, and alerts are then ignored) and a clearly accountable clinical response to each alert. Evaluations should use robust designs, such as cluster-randomised or stepped-wedge trials or well-controlled interrupted time-series analyses, and should report patient outcomes, costs and sustainability, particularly in resource-limited settings.

The immediate priority is to make structured, closed-loop communication a routine and measurable part of infection prevention and antibiotic care. That means organising daily work so that relevant information is heard, decisions are explained and someone is accountable for follow-through.

References

Baur D, Gladstone BP, Burkert F, Carrara E, Foschi F, Döbele S, Tacconelli E. Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. The Lancet Infectious Diseases. 2017 Sep 1;17(9):990-1001.
Article DOI

Bonaconsa C, Mbamalu O, Surendran S, George A, Mendelson M, Charani E. Optimizing infection control and antimicrobial stewardship bedside discussion: a scoping review of existing evidence on effective healthcare communication in hospitals. Clinical microbiology and infection. 2024 Mar 1;30(3):336-52.
Article DOI

Banerjee R, Komarow L, Li Y, Mau D, Dodd A, Geres H, Greenwood-Quaintance K, Adler A, Baliga S, Chowers M, Chrysos G. Fast antimicrobial susceptibility testing for gram-negative bacteremia: the FAST randomized clinical trial. JAMA. 2026 May 26;335(20):1762-73.
Article DOI

Science Factors.

Inside a Legume Root Nodule: Building the Network for Nitrogen Fixation and Sustainable Agriculture

Dr. Senjuti Sinharoy
0
What is the importance of nitrogen fixation? Nitrogen is one of the essential nutrients required for plant growth. Although nearly 78% of the Earth's atmosphere...

Beyond Potency: What Defines the Next Generation Selective HDAC8 Inhibitor?

Dr. Kondapalli Venkata Gowri. Chandra Sekhar
0
Histone deacetylases (HDACs) regulate the acetylation state of histone and non-histone proteins and therefore affect transcription, chromatin organization, cell cycle control and various signalling...

Overcoming Chemotherapy Resistance by Targeting Cancer’s Cellular Defences

Dr. N. Rajendra Prasad
0
Why does chemotherapy stop working? One of the greatest challenges in cancer treatment is not simply finding drugs that kill cancer cells, but understanding...

Understanding Antibiotic Resistance Through the Structure and Function of Bacterial Enzymes

Dr. Immanuel Dhanasingh
0
When life-saving medicines stop working Imagine having an infection that was once easily treated with antibiotics, but the same medicines no longer work. This is...

From engineered tissues to organ-on-a-chip: How bioengineering is transforming biomedical research and regenerative medicine

Prof. Sanjeev Kumar Mahto
0
Biomedical engineering is increasingly at the interface of living and engineered systems. Many biological questions are still difficult to answer using standard two-dimensional (2D)...

Beyond Memory Loss: A Metabolic View of Cognitive Decline and Dementia

Prof. Rameshwar Nath Chaurasia
0
Looking beyond symptoms Memory loss is one of the best-known signs of dementia, but it is only the visible part of a much more complex...

Beneath the Surface: Understanding Rhizosphere Interactions and Plant Development for Sustainable Agriculture

Dr. Mukesh Jain
0
Beneath every plant lies the rhizosphere, the narrow zone of soil surrounding the roots where plants and microbes constantly exchange chemical signals. Plants release...

The Cell’s Nuclear RNA Quality Control: Finding Faulty Messages and Fine-Tuning Gene Activity

Dr. Biswadip Das
0
Error-Prone mRNA Biogenesis In all eukaryotes, mRNA biogenesis consists of the transcription of the protein-coding genes by RNA polymerase II, capping of the primary transcript...